CATSPERT

Summary

CATSPERT (catsper channel auxiliary subunit tau, HGNC:14438) is a protein-coding gene on chromosome 2q33.1, encoding Cation channel sperm-associated targeting subunit tau (Q53TS8). Auxiliary component of the CatSper complex, a complex involved in sperm cell hyperactivation.

An autosomal recessive form of juvenile amyotrophic lateral sclerosis was originally mapped to a region of chromosome 2 that includes this gene. The encoded protein contains a calcium-dependent membrane targeting C2 domain. This domain is often found in proteins that are involved in membrane trafficking and signal transduction.

Source: NCBI Gene 151254 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 161 total — 1 pathogenic
• Phenotypes (HPO): 4
• MANE Select transcript: NM_001168221

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14438
Approved symbol	CATSPERT
Name	catsper channel auxiliary subunit tau
Location	2q33.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ25351
Ensembl gene	ENSG00000155754
Ensembl biotype	protein_coding
OMIM	619776
Entrez	151254

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 7 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000286195, ENST00000439140, ENST00000439802, ENST00000450242, ENST00000482942, ENST00000957096, ENST00000957097, ENST00000957098

RefSeq mRNA: 4 — MANE Select: NM_001168221 NM_001168216, NM_001168217, NM_001168221, NM_152525

CCDS: CCDS2349, CCDS54428, CCDS54429, CCDS54430

Canonical transcript exons

ENST00000439140 — 16 exons

Exon	Start	End
ENSE00001076310	201547505	201547610
ENSE00001076311	201604611	201604697
ENSE00001076312	201603224	201603275
ENSE00001076313	201601739	201601884
ENSE00001076316	201571941	201572020
ENSE00001076317	201565729	201565872
ENSE00001076318	201582095	201582217
ENSE00001076321	201545543	201545621
ENSE00001076322	201575282	201575326
ENSE00001076323	201574209	201574277
ENSE00001200709	201536021	201536320
ENSE00001200712	201537436	201537479
ENSE00001401463	201618900	201619178
ENSE00001704203	201487421	201487902
ENSE00001778001	201491169	201494759
ENSE00003568413	201495895	201495969

Expression profiles

Bgee: expression breadth ubiquitous, 159 present calls, max score 95.63.

FANTOM5 (CAGE): breadth broad, TPM avg 0.6685 / max 81.1953, expressed in 293 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
33237	0.6020	276
33235	0.0665	18

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	95.63	gold quality
left testis	UBERON:0004533	88.83	gold quality
right testis	UBERON:0004534	88.16	gold quality
testis	UBERON:0000473	86.92	gold quality
calcaneal tendon	UBERON:0003701	85.68	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.25	gold quality
buccal mucosa cell	CL:0002336	84.10	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.17	gold quality
adrenal tissue	UBERON:0018303	80.14	gold quality
colonic epithelium	UBERON:0000397	79.74	gold quality
secondary oocyte	CL:0000655	72.99	gold quality
tendon	UBERON:0000043	71.51	gold quality
Brodmann (1909) area 9	UBERON:0013540	69.53	gold quality
mucosa of paranasal sinus	UBERON:0005030	68.64	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	67.71	gold quality
apex of heart	UBERON:0002098	66.89	gold quality
corpus callosum	UBERON:0002336	66.69	gold quality
oocyte	CL:0000023	66.29	gold quality
anterior cingulate cortex	UBERON:0009835	65.84	gold quality
spinal cord	UBERON:0002240	65.37	gold quality
lower esophagus mucosa	UBERON:0035834	64.87	gold quality
pituitary gland	UBERON:0000007	64.59	gold quality
adenohypophysis	UBERON:0002196	64.27	gold quality
left adrenal gland	UBERON:0001234	63.97	gold quality
lower lobe of lung	UBERON:0008949	63.87	silver quality
cerebellar hemisphere	UBERON:0002245	63.67	gold quality
right atrium auricular region	UBERON:0006631	63.45	gold quality
right adrenal gland	UBERON:0001233	63.28	gold quality
right frontal lobe	UBERON:0002810	63.26	gold quality
hypothalamus	UBERON:0001898	63.25	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	5.27

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

29 targeting CATSPERT, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-9718	99.94	68.91	918
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-4719	99.73	72.10	3329
HSA-MIR-4743-3P	99.62	68.12	2095
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-182-3P	99.57	67.57	825
HSA-MIR-2053	99.57	69.15	1635
HSA-MIR-12122	99.56	69.33	1672
HSA-MIR-569	99.42	66.32	1009
HSA-MIR-519D-5P	99.41	69.30	2057
HSA-MIR-889-3P	99.40	69.76	2103
HSA-MIR-377-3P	99.37	70.18	1905
HSA-MIR-4434	99.10	67.01	1984
HSA-MIR-5703	99.10	67.09	2053
HSA-MIR-4424	98.91	70.33	1145
HSA-MIR-382-3P	98.83	67.10	1074
HSA-MIR-5197-3P	98.71	67.05	1905
HSA-MIR-628-5P	98.36	67.74	844
HSA-MIR-6773-3P	98.17	65.51	1213
HSA-MIR-218-2-3P	98.08	67.21	601
HSA-MIR-4303	98.01	68.13	2304
HSA-MIR-597-3P	96.46	68.03	1035
HSA-MIR-152-5P	96.42	66.59	960

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	C2cd6	ENSMUSG00000072295
rattus_norvegicus	C2cd6	ENSRNOG00000012637

Protein

Protein identifiers

Cation channel sperm-associated targeting subunit tau — Q53TS8 (reviewed: Q53TS8)

Alternative names: Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 11 protein, C2 calcium-dependent domain-containing protein 6, Catsper channel auxiliary subunit tau

All UniProt accessions (2): Q53TS8, A0A140VJE2

UniProt curated annotations — full annotation on UniProt →

Function. Auxiliary component of the CatSper complex, a complex involved in sperm cell hyperactivation. Sperm cell hyperactivation is needed for sperm motility which is essential late in the preparation of sperm for fertilization. Required for CatSper complex targeting and trafficking into the quadrilinear nanodomains. Targets the preassembled CatSper complexes to elongating flagella, where it links the channel-carrying vesicles and motor proteins.

Subunit / interactions. Component of the CatSper complex or CatSpermasome composed of the core pore-forming members CATSPER1, CATSPER2, CATSPER3 and CATSPER4 as well as auxiliary members CATSPERB, CATSPERG, CATSPERD, CATSPERE, CATSPERZ, CATSPERT, CATSPERQ, CATSPERH and EFCAB9. HSPA1 may be an additional auxiliary complex member. The core complex members CATSPER1, CATSPER2, CATSPER3 and CATSPER4 form a heterotetrameric channel. The auxiliary CATSPERB, CATSPERG, CATSPERD and CATSPERE subunits form a pavilion-like structure over the pore which stabilizes the complex through interactions with CATSPER4, CATSPER3, CATSPER1 and CATSPER2 respectively. SLCO6C1 interacts with CATSPERE and CATSPERH interacts with CATSPERB, further stabilizing the complex. CATSPERT interacts at least with CATSPERD and is required for targeting the CatSper complex in the flagellar membrane.

Subcellular location. Cell projection. Cilium. Flagellum membrane.

Tissue specificity. Expressed in testis (at protein level).

Disease relevance. Spermatogenic failure 68 (SPGF68) [MIM:619805] An autosomal recessive male infertility disorder characterized by globozoospermia. Affected individuals have a normal sperm count, but spermatozoa are round-headed and lack the acrosome. In addition to pure globozoospermia, some patients have a mixture of acrosomeless spermatozoa and spermatozoa with small or detached acrosomes, which is defined as acrosomal hypoplasia. The disease may be caused by variants affecting the gene represented in this entry.

Isoforms (4)

UniProt ID	Names	Canonical?
Q53TS8-4	1, L	yes
Q53TS8-1	2, S
Q53TS8-2	3
Q53TS8-3	4

RefSeq proteins (4): NP_001161688, NP_001161689, NP_001161693, NP_689738 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000008	C2_dom	Domain
IPR031462	CTSRT	Family
IPR048363	CTSRT_C2	Domain

Pfam: PF15729

UniProt features (18 total): splice variant 5, region of interest 4, sequence variant 3, sequence conflict 3, chain 1, domain 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q53TS8-F1	39.82	0.03

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 86 (showing top): TGCGCANK_UNKNOWN, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_MALE_GAMETE_GENERATION, GOBP_SPERM_CAPACITATION, GOBP_ANATOMICAL_STRUCTURE_MATURATION, GOBP_CELL_MATURATION, GOBP_CILIUM_MOVEMENT, GOBP_CILIUM_OR_FLAGELLUM_DEPENDENT_CELL_MOTILITY, GOBP_CELLULAR_PROCESS_INVOLVED_IN_REPRODUCTION_IN_MULTICELLULAR_ORGANISM, TTGGAGA_MIR5155P_MIR519E, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, GOBP_LOCALIZATION_WITHIN_MEMBRANE, GOCC_VOLTAGE_GATED_CALCIUM_CHANNEL_COMPLEX, GOCC_MOTILE_CILIUM, GOCC_CATION_CHANNEL_COMPLEX

GO Biological Process (4): spermatogenesis (GO:0007283), flagellated sperm motility (GO:0030317), sperm capacitation (GO:0048240), vesicle-mediated transport to the plasma membrane (GO:0098876)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (7): CatSper complex (GO:0036128), sperm principal piece (GO:0097228), plasma membrane (GO:0005886), cilium (GO:0005929), membrane (GO:0016020), motile cilium (GO:0031514), cell projection (GO:0042995)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
developmental process involved in reproduction	2
male gamete generation	1
cilium-dependent cell motility	1
cilium movement involved in cell motility	1
sperm motility	1
spermatid development	1
cellular process involved in reproduction in multicellular organism	1
cell maturation	1
exocytosis	1
vesicle-mediated transport	1
localization within membrane	1
binding	1
voltage-gated calcium channel complex	1
sperm flagellum	1
membrane	1
cell periphery	1
intraciliary transport particle	1
membrane-bounded organelle	1
plasma membrane bounded cell projection	1
cilium	1

Protein interactions and networks

STRING

502 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CATSPERT	SPACDR	Q8IZ16	678
CATSPERT	EFCAB9	A8MZ26	626
CATSPERT	TSACC	Q96A04	569
CATSPERT	C22orf23	Q9BZE7	540
CATSPERT	SPATA16	Q9BXB7	539
CATSPERT	TMEM237	Q96Q45	522
CATSPERT	FLACC1	Q96Q35	511
CATSPERT	CCDC62	Q6P9F0	500
CATSPERT	ZPBP	Q9BS86	480
CATSPERT	GKAP1	Q5VSY0	479
CATSPERT	ACTRT2	Q8TDY3	474
CATSPERT	DPY19L2	Q6NUT2	467
CATSPERT	ODAD4	Q96NG3	461
CATSPERT	DNAH17	Q9UFH2	457
CATSPERT	CCDC54	Q8NEL0	436

IntAct

183 interactions, top by confidence:

A	B	Type	Score
C2CD6	GOLGA2	psi-mi:“MI:0915”(physical association)	0.720
C2CD6	KRT31	psi-mi:“MI:0915”(physical association)	0.720
KRT31	C2CD6	psi-mi:“MI:0915”(physical association)	0.720
GOLGA2	C2CD6	psi-mi:“MI:0915”(physical association)	0.720
KRT13	C2CD6	psi-mi:“MI:0915”(physical association)	0.560
KRT15	C2CD6	psi-mi:“MI:0915”(physical association)	0.560
CDR2	C2CD6	psi-mi:“MI:0915”(physical association)	0.560
TRAF1	C2CD6	psi-mi:“MI:0915”(physical association)	0.560
MTUS2	C2CD6	psi-mi:“MI:0915”(physical association)	0.560
KRT40	C2CD6	psi-mi:“MI:0915”(physical association)	0.560
DNAJA3	C2CD6	psi-mi:“MI:0915”(physical association)	0.560
C2CD6	TRIM54	psi-mi:“MI:0915”(physical association)	0.560
CARD9	C2CD6	psi-mi:“MI:0915”(physical association)	0.560
C2CD6	TFIP11	psi-mi:“MI:0915”(physical association)	0.560
C2CD6	KRT13	psi-mi:“MI:0915”(physical association)	0.560
C2CD6	KRT40	psi-mi:“MI:0915”(physical association)	0.560
C2CD6	DNAJA3	psi-mi:“MI:0915”(physical association)	0.560
C2CD6	CARD9	psi-mi:“MI:0915”(physical association)	0.560
TFIP11	C2CD6	psi-mi:“MI:0915”(physical association)	0.560
C2CD6	KRT15	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (79): ALS2CR11 (Two-hybrid), ALS2CR11 (Two-hybrid), ALS2CR11 (Two-hybrid), ALS2CR11 (Two-hybrid), ALS2CR11 (Two-hybrid), ALS2CR11 (Two-hybrid), ALS2CR11 (Two-hybrid), ALS2CR11 (Two-hybrid), ALS2CR11 (Two-hybrid), ALS2CR11 (Two-hybrid), ALS2CR11 (Two-hybrid), ALS2CR11 (Two-hybrid), BRCA1 (Two-hybrid), ALS2CR11 (Two-hybrid), ALS2CR11 (Two-hybrid)

ESM2 similar proteins: A0A509AC44, A3LU54, A5K168, A6QLI2, A6ZQG7, A7TIZ4, A8X9H4, B3LAJ9, O16883, P09959, P16893, P25558, P28466, P32567, P33736, P35177, P36124, P36168, P38970, P39717, P40418, P40456, P40480, P42666, P43554, P47868, P53125, P69192, P69193, P87152, Q08236, Q08957, Q12202, Q26015, Q4XZY3, Q53TS8, Q59PW0, Q5UQK5, Q6BGY8, Q6BIF0

Diamond homologs: A0A5F8MPU3, Q53TS8

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 62 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
intermediate filament organization	6	25.8×	7e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

161 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	130
Likely benign	16
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1345025	NM_001168221.2(C2CD6):c.338A>G (p.His113Arg)	Pathogenic

SpliceAI

3410 predictions. Top by Δscore:

Variant	Effect	Δscore
2:201536205:T:TA	donor_gain	1.0000
2:201545537:TCTTA:T	donor_loss	1.0000
2:201545538:CTTAC:C	donor_loss	1.0000
2:201545539:TTA:T	donor_loss	1.0000
2:201545540:T:TG	donor_loss	1.0000
2:201545541:A:AC	donor_gain	1.0000
2:201545541:A:AG	donor_loss	1.0000
2:201545542:C:CC	donor_gain	1.0000
2:201545542:CCTA:C	donor_gain	1.0000
2:201545545:A:AC	donor_gain	1.0000
2:201545545:ACT:A	donor_gain	1.0000
2:201545546:C:CC	donor_gain	1.0000
2:201545546:CTC:C	donor_gain	1.0000
2:201545619:TTC:T	acceptor_gain	1.0000
2:201545620:TCCT:T	acceptor_loss	1.0000
2:201547500:ATTAC:A	donor_loss	1.0000
2:201547501:TTA:T	donor_loss	1.0000
2:201547502:TA:T	donor_loss	1.0000
2:201547504:C:G	donor_loss	1.0000
2:201571939:A:AC	donor_gain	1.0000
2:201571940:C:CC	donor_gain	1.0000
2:201571940:CGT:C	donor_gain	1.0000
2:201571940:CGTCA:C	donor_gain	1.0000
2:201572016:TTTAA:T	acceptor_gain	1.0000
2:201572017:TTAA:T	acceptor_gain	1.0000
2:201572018:TAA:T	acceptor_gain	1.0000
2:201572021:C:CC	acceptor_gain	1.0000
2:201582226:C:CT	acceptor_gain	1.0000
2:201582227:A:T	acceptor_gain	1.0000
2:201601881:CTGA:C	acceptor_gain	1.0000

AlphaMissense

12098 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:201574245:G:C	F239L	0.993
2:201574245:G:T	F239L	0.993
2:201574247:A:G	F239L	0.993
2:201574271:A:G	C231R	0.993
2:201582171:A:G	L188P	0.993
2:201547559:T:A	K343N	0.991
2:201547559:T:G	K343N	0.991
2:201574246:A:G	F239S	0.991
2:201547588:A:C	Y334D	0.989
2:201547548:A:G	L347S	0.988
2:201582188:A:C	N182K	0.988
2:201582188:A:T	N182K	0.988
2:201547558:C:G	A344P	0.987
2:201547588:A:G	Y334H	0.986
2:201574269:G:C	C231W	0.986
2:201582111:A:G	L208P	0.986
2:201582130:C:A	G202W	0.986
2:201547560:T:A	K343I	0.985
2:201547570:A:G	W340R	0.985
2:201547570:A:T	W340R	0.985
2:201547608:A:G	L327P	0.985
2:201571982:A:C	F264L	0.985
2:201571982:A:T	F264L	0.985
2:201571984:A:G	F264L	0.985
2:201572019:A:G	L252S	0.985
2:201574222:C:T	G247E	0.985
2:201582216:A:T	V173D	0.985
2:201601749:A:G	F169S	0.985
2:201603265:A:G	L110P	0.985
2:201571983:A:G	F264S	0.984

dbSNP variants (sampled 300 via entrez): RS1000021516 (2:201486942 C>G,T), RS1000022273 (2:201538710 G>A), RS1000042810 (2:201536986 G>A), RS1000077610 (2:201495246 G>C), RS1000088578 (2:201616754 G>A,C), RS1000090374 (2:201592213 G>A,C), RS1000114253 (2:201538856 C>T), RS1000128718 (2:201545907 A>G), RS1000144297 (2:201579239 T>A), RS1000154686 (2:201544564 TTCCTCTGCATAAACACAC>T), RS1000184795 (2:201579089 C>T), RS1000200519 (2:201530817 C>T), RS1000216491 (2:201584355 G>A), RS1000283229 (2:201539078 T>C), RS1000317054 (2:201599015 G>A)

Disease associations

OMIM: gene MIM:619776 | disease phenotypes: MIM:619805

GenCC curated gene-disease

Mondo (2): spermatogenic failure 68 (MONDO:0030721), prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

4 total (4 of 4 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0003251	Male infertility
HP:0011462	Young adult onset
HP:0012205	Globozoospermia

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST009665_1	Breast cancer	2.000000e-08
GCST010105_155	Nicotine dependence symptom count	1.000000e-06
GCST012145_18	Ferritin levels	2.000000e-06
GCST90002390_463	Mean corpuscular hemoglobin	3.000000e-09

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0009262	nicotine dependence symptom count
EFO:0004459	ferritin measurement
EFO:0004527	mean corpuscular hemoglobin

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

7 total (human), top 7 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
pirinixic acid	increases activity, affects binding, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Estradiol	decreases expression	1
Antirheumatic Agents	increases expression	1
Permethrin	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer